Research
Education
Solutions
Sign In
EN
EN - English
CN - 中文
DE - Deutsch
ES - Español
KR - 한국어
IT - Italiano
FR - Français
PT - Português
TR - Turkish
JA - Japanese
Vincenza Conteduca has not added Biography.
If you are Vincenza Conteduca and would like to personalize this page please email our Author Liaison for assistance.
Early outcome prediction on 18F-fluorocholine PET/CT in metastatic castration-resistant prostate cancer patients treated with abiraterone.
Oncotarget Dec, 2014 | Pubmed ID: 25504434
Circulating AR copy number and outcome to enzalutamide in docetaxel-treated metastatic castration-resistant prostate cancer.
Oncotarget Jun, 2016 | Pubmed ID: 27191887
Systemic immune-inflammation index predicts the clinical outcome in patients with metastatic renal cell cancer treated with sunitinib.
Oncotarget 08, 2016 | Pubmed ID: 27409344
Cell-free DNA as a diagnostic marker for cancer: current insights.
OncoTargets and therapy , 2016 | Pubmed ID: 27822059
Circulating androgen receptor combined with 18F-fluorocholine PET/CT metabolic activity and outcome to androgen receptor signalling-directed therapies in castration-resistant prostate cancer.
Scientific reports Nov, 2017 | Pubmed ID: 29138500
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS
Samanta Salvi1,
Vincenza Conteduca1,
Filippo Martignano1,
Giorgia Gurioli1,
Daniele Calistri1,
Valentina Casadio1
1, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS
Privacy
Terms of Use
Policies
Contact Us
Recommend to library
JoVE NEWSLETTERS
JoVE Journal
Methods Collections
JoVE Encyclopedia of Experiments
Archive
JoVE Core
JoVE Business
JoVE Science Education
JoVE Lab Manual
Faculty Resource Center
Authors
Librarians
Access
ABOUT JoVE
Copyright © 2024 MyJoVE Corporation. All rights reserved
